TIDMRENE

RNS Number : 1376F

ReNeuron Group plc

14 July 2021

ReNeuron Group plc

("ReNeuron" or the "Company")

Board Change

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that Barbara Staehelin has joined the Board as senior independent Non-Executive Director with immediate effect.

Ms. Staeheli n's career in the international life sciences and technology sectors spans over 30 years and includes consulting, CEO and Chair roles. She has led and co-founded four life science companies and is currently on the Board as President of the Audit and Risk Committee and a member of the Investment Committee at Assura Group , which operates in the health insurance sector and which is headquartered in Switzerland. Ms. Staehelin's background is in biochemistry and until 2006, she was a member of the Global Executive Committee of Roche Diagnostics.

Ms. Staehelin holds a Directors Certificate from Harvard University, USA as well as executive education in new concepts for boards from University St. Gallen, Switzerland, health economy from the European School for Health Economics, France and an MBA from INSEAD Fontainebleau, France.

Iain Ross, Chairman of ReNeuron, commented: "I am delighted to welcome Barbara to the ReNeuron Board as a Non-Executive Director. She brings a wealth of market development experience in the medical services and biotech sectors and a strong track record in corporate governance. My colleagues and I look forward to working with her during this transformational time for ReNeuron."

Disclosures in accordance with the AIM Rules

Barbara Regina Staehelin, 58, is, or has been, a director or partner of the following companies or partnerships during the past five years:

Current Partnerships and Directorships:

Axicos AG

Assura Holding SA

Assura SA

Assura-Basis SA

Figeas SA

ABC Invest & Medical GmbH

Dybly AG

Ava AG

Prior Partnerships & Directorships:

Keires AG

In 2009, Ms Staehelin was appointed as turnaround CEO of SIRS-Lab GmbH, a molecular diagnostics company headquartered in Germany. Having successfully led one funding round and the completion of a clinical trial, in July 2012, Ms Staehelin resigned from her position and worked her notice period. On 1 March 2013, as a result of an inability to raise additional capital, the company entered into a Court ordered liquidation and then was dissolved on 3 November 2013.

In 1997, Ms Staehelin became Chairman of GetWellness AG which was voluntarily dissolved in 2006 in a solvent wind-up and the resulting corporate entity was then put into liquidation.

Ms. Staehelin has no holding in ReNeuron.

There are no further disclosures required in accordance with AIM Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies.

ENDS

Contacts:

 
 ReNeuron                                                        www.reneuron.com/investors 
 Olav Hellebø, Chief Executive                                         Via Walbrook PR 
  Officer 
 
 Stifel Nicolaus Europe Limited (NOMAD 
  and Joint Broker) 
  Ben Maddison, Stewart Wallace                                         +44 (0)20 7710 7600 
 
 Allenby Capital Limited (Joint Broker)                                 +44 (0)20 3328 5656 
 James Reeve/George Payne (Corporate 
  Finance) 
 Stefano Aquilino (Sales & Corporate 
  Broking) 
 
 Walbrook PR (Media & Investor Relations)    +44 (0)20 7933 8780 or reneuron@walbrookpr.com 
                                                          +44 (0)7980 541 893 / +44 (0)7407 
 Paul McManus, Alice Woodings                                                       804 654 
 

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments for disease with significant unmet needs. The Company's lead cell therapy candidate is in clinical development for the blindness-causing disease, retinitis pigmentosa.

ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the central nervous system and other disorders. The Company also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make allogeneic tissue cells of choice; in-house programmes are currently focused on treatments for blood cancers and diabetes.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOARJMRTMTMBBIB

(END) Dow Jones Newswires

July 14, 2021 02:00 ET (06:00 GMT)

Reneuron (LSE:RENE)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024 Haga Click aquí para más Gráficas Reneuron.
Reneuron (LSE:RENE)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024 Haga Click aquí para más Gráficas Reneuron.